Are Besudil Mesylate Tablets a targeted drug? which type

Belumosudil mesylate tablets (Belumosudil) does belong to the category of targeted drugs. Its target is ROCK2 (Rho-related protein kinase 2) and it is a selective ROCK2 inhibitor. ROCK2 is a member of the Rho kinase family and plays a key role in cytoskeletal regulation, cell migration, proliferation and fibrosis. Besudil achieves therapeutic effects by specifically inhibiting ROCK2 activity, regulating the immune system and anti-fibrotic response.

ROCK2 plays an important role in the pathogenesis of chronic graft-versus-host disease (cGVHD). In patients with cGVHD, the ROCK2 signaling pathway is overactive, leading to abnormal activation of immune cells and the formation of fibrotic tissue, causing multiple organ damage. Besudil inhibits the release of pro-inflammatory cytokines and the fibrosis process by interfering with ROCK2-related signaling, thereby alleviating tissue damage and clinical symptoms.

Unlike traditional immunosuppressants, Besudil targets specific molecular targets to reduce suppression of the overall immune system, reducing the risk of infection and other systemic side effects. Its targeting mechanism gives the drug unique advantages in the treatment of refractory cGVHD, providing patients with new treatment options.

In addition, besudil also plays a role in regulating the balance between regulatory T cells (Treg) and helper T cells (Th17), which is critical in autoimmune diseases and graft-versus-host disease. By affecting this cellular immune network, besudil effectively reduces immune-mediated inflammation and tissue damage.

Clinical studies have shown that besudil shows good efficacy and safety when used alone or in combination with other immunosuppressants. Its precision as a targeted drug helps maximize therapeutic effects while reducing unnecessary immunosuppression.

Reference: https://www.drugs.com/pro/rezurock.html